About Erik Tvetenstrand, ARK Analyst
Erik left ARK in 2015. As an analyst on the Genomic Revolution team he covered diverse companies and issues in the field of biotechnology and health care.
Research by Erik Tvetenstrand, ARK Analyst
September 14, 2015 | by Erik Tvetenstrand, ARK Analyst | Health
It’s almost impossible to imagine a pharma company giving up on a patent. The impossible can happen, as it did in August 2014, when Vertex Pharmaceuticals gave up on Incivek, its flagship hepatitis C treatment. “This decision has been taken in view of available alternative treatments and the diminishing market demand for Incivek,” read a […]May 18, 2015 | by Erik Tvetenstrand, ARK Analyst | Health
Healthcare investors likely remember the devastating impact of generic drugs on drug prices in the late 1980s. While traditional firms struggled, many successful biotechnology companies took root during this turbulent period. Focusing on the growing field of biologic medicine, many biotech firms were acquired by pharmaceutical companies looking to lower research and development costs, while […]